Quantum BioPharma Ltd. (QNTM) Announces Key Milestones; Price Target $12.80
Quantum BioPharma Ltd. (QNTM) Announces Key Milestones; Price Target $12.80
LOS ANGELES, CA / ACCESSWIRE / August 30, 2024 / Quantum BioPharma Ltd. (QNTM) marks a significant milestone with the successful launch of unbuzzd on Amazon. This development coincides with the Company's rebranding and ticker change to QNTM. Additionally, recent ethics approval in Australia for a Phase-1 study of Lucid-MS represents a crucial advancement in the development of a novel treatment for Multiple Sclerosis.
2024年8月30日，量子生物製藥股份有限公司（QNTM）在亞馬遜成功推出unbuzzd，這標誌着該公司的里程碑式進展。此次開發與公司的重新品牌和股票代碼更改爲QNTm同時進行。此外，最近在澳洲獲得倫理批准進行Lucid-MS的1期研究，爲多發性硬化的新型治療的開發取得了重要進展。
We maintain our Buy-Venture rating and have adjusted our target price to $12.80 per share, reflecting confidence in Quantum BioPharma's pioneering efforts in addressing brain disorders and alcohol health. The Company's strong pipeline includes Lucid-MS, targeting progressive Multiple Sclerosis, and unbuzzd, a formulation designed to expedite alcohol metabolism. With marketing experts Kevin Harrington and Gerry David leading unbuzzd's market launch, Quantum BioPharma is positioned for substantial growth.
我們保持買入-創業公司評級，並將目標價調整爲每股12.80美元，反映出對量子生物製藥在大腦疾病和酒精健康領域開拓性工作的信心。該公司的強大產品線包括針對進行性多發性硬化的Lucid-MS和旨在加速酒精代謝的unbuzzd。在市場營銷專家Kevin Harrington和Gerry David的帶領下，unbuzzd的市場推介，使得量子生物製藥處於實現巨大增長的位置。
For access to our research report on Quantum BioPharma, please click here.
要獲取我們對量子生物製藥的研究報告，請點擊這裏。
For more information on Quantum BioPharma, visit .
了解更多關於量子生物製藥的信息，請訪問。
For more information on Singular Research, visit .
了解更多關於Singular Research的信息，請訪問。
Singular Research
Research@SingularResearch.com
818-222-6234
Singular Research
Research@SingularResearch.com
818-222-6234
SOURCE: Singular Research
來源：Singular Research
譯文內容由第三人軟體翻譯。